Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design

American Journal of Cardiology

Volumn 83, Issue 4, 1999, Pages 477-481

  Dickstein, Kenneth ^a   Kjekshus, John ^b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; LOSARTAN; PLACEBO; RAMIPRIL;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUDDEN DEATH; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; DOUBLE-BLIND METHOD; HUMANS; LOSARTAN; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033557542     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00898-4     Document Type: Article

References (30)

1. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. JAMA 1995;18:1450-1455.
2. Latini R, Maggioni A, Fiather M, Sleight P, Tognoni G. Ace inhibitor use in patients with myocardial infarction. Circulation 1995;92:3132-3137.
3. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:812-828.
4. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy E, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. On behalf of the SAVE Investigators, effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
5. Køber L, Torp-Pedersen C, Carlson JE, Bagger H, Eliasen P, Lynborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;33:1670-1676.
6. Ambrosioni E, Borghi C, Magnani B, for the SMILE Study Investigators. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.
7. ISIS-4 (fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulfate in over 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
8. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
9. Hall S, Sapsford R, Megary S, Ball S. Inhibition of the renin-angiotensin system after acute myocardial infarction-treat first, select later? Heart 1996;76:73-78.
10. Aldigier JC. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin 11 increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-295.
11. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-890.
12. Lacourciere Y, Brunner H, Irwin R, Karlberg B, Ramsay L, Snavely D, Dobbins TW, Faison EP, Nelson EB, and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-1393.
13. Goldberg A, Sweet C. Efficacy and safety of losartan. Can J Cardiol 1995;11(suppl F):27F-32F.
14. Gottleib S, Dickstein K, Fleck E, Kostis J, Levine B, LeJemtal T, DeKock M. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-1609.
15. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995;91:691-697.
16. Dickstein K, Chang P, Willenheimer R, Haunsø S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J Am Coll Cardiol 1995;23:438-444.
17. Klinger G, Jaramillo N, Ikram H. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. J Am Coll Cardiol 1996;27:29:205A.
18. Pitt B, Segal R, Martinez FA, Meurers G, Cowley A, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-752.
19. Viskin S, Kitzis I, Lev E, Zak I, Heller K, Villa Y, Zajarias A, Laniado S, Belhassen B. Treatment with beta-adrenergic agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-1332.
20. Thomas G, Ferrier G, Hewlett S. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther 1996;278:1090-1097.
21. Harada K, Komuro I, Hayashi D, Sugaya T, Murakami K, Tazaki Y. Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation 1998;97:315-317.
22. Rump L, Oberhauser V, Schwerfeger E, Scholmeyer P. Experimental evidence to support ELITE Lancet 1998;351:644-645.
23. Pitt B. Evaluation of losartan in the elderly (ELITE) trial: clinical implications. Eur Heart J 1997;18:1197-1199.
24. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin 11 type I receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-2282.
25. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Maruyama K, Horiuch M, et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attentuated response to ATI receptor-mediated pressor and chronotropic effects. J Clin Invest 1998;101:527-535.
26. Rodrigo E, Maeso R, Munoz-Garcia R, Navarro-Cid J, Ruilope L, Cachofeiro V, Lahera V. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. Hypertension 1997;15:613-618.
27. Rogg H, de Gasparo M, Graedel E, Stultz P, Burkart F, Eberhard M, Erne P. Angiotensin II∼receptor subtypes in human atria and evidence for alteration in patients with cardiac dysfunction. Eur Heart J 1996;17:1112-1120.
28. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin 11 type I receptor antagonists in rats with heart failure. Role of kinins and angiotensin 11 type 2 receptors. J Clin Invest 1997;99:1926-1935.
29. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 1996;27:714-719.
30. Kober L, Torp-Pedersen C, Pedersen O, Hoiberg S, Camm A. Prognostic impact of post infarction congestive heart failure. Cardiol Rev 1997:14:39-46.